Apotex shareholders sell $540M in secondary offering, among Canada's largest health deals
What's the deal? Apotex Health Corp.Dealroom has a profile for this one. Try Dealroom → shareholders have agreed to sell 22,058,825 common shares at $34.00 each in a bought-deal secondary offering worth about C$750 million (roughly $540 million). The Toronto company announced the deal on September 14, 2026, with closing expected on or about September 18.
Who's selling? The selling shareholders are SK Capital PartnersDealroom has a profile for this one. Try Dealroom →, API Investment LPDealroom has a profile for this one. Try Dealroom → (SherfamDealroom has a profile for this one. Try Dealroom →), and Allan Oberman. Apotex itself will not receive any proceeds — the net proceeds go directly to those investors.
Who's leading it? A syndicate of underwriters agreed to purchase the shares. RBC Capital MarketsDealroom has a profile for this one. Try Dealroom →, TD SecuritiesDealroom has a profile for this one. Try Dealroom →, and ScotiabankDealroom has a profile for this one. Try Dealroom → act as joint lead bookrunners, with BMO Capital MarketsDealroom has a profile for this one. Try Dealroom → and Jefferies as joint bookrunners.
The details: The shareholders granted the underwriters an over-allotment option to buy up to 3,308,823 additional shares — 15% of the offering — within 30 days of closing. The shares are offered via prospectus supplement across Canada and may also be placed privately in the US and internationally.
The signal: The offering ranks among the largest of its kind, sitting in roughly the 91st percentile of all-time post-IPO secondary rounds in Canada's health sector, based on a sample of 75 deals. It marks a significant liquidity event for Apotex's backers rather than fresh capital for the business.
Image credit: Generated with Gemini
